Watson C, Tallentire CW, Ramage JK, Srirajaskanthan R, Leeuwenkamp OR, Fountain D. Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review. World J Gastroenterol 2020; 26(25): 3686-3711 [PMID: 32742136 DOI: 10.3748/wjg.v26.i25.3686]
Corresponding Author of This Article
Donna Fountain, PhD, Research Scientist, PHMR Health Economics, Pricing and Reimbursement, PHMR Head Office, London NW1 8XY, United Kingdom. donnafountain@phmr.com
Research Domain of This Article
Oncology
Article-Type of This Article
Systematic Reviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Watson C, Tallentire CW, Ramage JK, Srirajaskanthan R, Leeuwenkamp OR, Fountain D. Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review. World J Gastroenterol 2020; 26(25): 3686-3711 [PMID: 32742136 DOI: 10.3748/wjg.v26.i25.3686]
World J Gastroenterol. Jul 7, 2020; 26(25): 3686-3711 Published online Jul 7, 2020. doi: 10.3748/wjg.v26.i25.3686
Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review
Catherine Watson, Craig William Tallentire, John K Ramage, Rajaventhan Srirajaskanthan, Oscar R Leeuwenkamp, Donna Fountain
Catherine Watson, Craig William Tallentire, Donna Fountain, PHMR Health Economics, Pricing and Reimbursement, London NW1 8XY, United Kingdom
John K Ramage, Rajaventhan Srirajaskanthan, Kings Health Partners NET centre, Kings College Hospital London, London SE5 9RS, United Kingdom
Oscar R Leeuwenkamp, Advanced Accelerator Applications, Geneva 1204, Switzerland
Author contributions: Watson C and Tallentire CW performed the research and analysed the data; they contributed to the manuscript equally; Ramage JK has reviewed the manuscript and offered invaluable contribution based on his disease expertise; Srirajaskanthan R also provided disease expertise; Leeuwenkamp OR and Fountain D designed and supervised the research. All authors contributed to writing the manuscript; all authors read and approved the final manuscript.
Conflict-of-interest statement: All the authors declare that they have no competing interests.
PRISMA 2009 Checklist statement: This study followed PRISMA guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Donna Fountain, PhD, Research Scientist, PHMR Health Economics, Pricing and Reimbursement, PHMR Head Office, London NW1 8XY, United Kingdom. donnafountain@phmr.com
Received: March 9, 2020 Peer-review started: March 9, 2020 First decision: March 31, 2020 Revised: June 4, 2020 Accepted: June 17, 2020 Article in press: June 17, 2020 Published online: July 7, 2020 Processing time: 120 Days and 0.3 Hours
Core Tip
Core tip: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are slow-growing cancers that arise from diffuse endocrine cells in the gastrointestinal tract and pancreas. An increased emphasis has been placed on health-related quality of life assessment in clinical studies, using reliable and validated patient-reported outcome instruments. Long-term therapeutic options provide symptomatic relief for patients with GEP-NETs, and can slow down or stabilise disease progression, but are not curative. Thus, understanding the impact of the long-term treatment options is particularly important. The aim of this study was to perform a systematic review to assess health-related quality of life focusing on patients with inoperable metastatic GEP-NETs undergoing different treatments in order to uncover areas for future research.
